514. The Effect of Probiotics on the Incidence of Clostridium difficile
Session: Poster Abstract Session: Healthcare Epidemiology: Updates in C. difficile
Thursday, October 4, 2018
Room: S Poster Hall
  • ID week poster 9.6.18.pdf (583.3 kB)
  • Background: Currently there is conflicting evidence regarding probiotics affecting the incidence and/or severity of Clostridium difficile infection (CDI). According to the IDSA guidelines, there is insufficient data to support the use of probiotics as primary prophylaxis of CDI. The primary objective of this study is to evaluate whether the administration of probiotics is efficacious for CDI prophylaxis in patients who are on antibiotics making them at increased risk for contracting CDI.

    Methods: The study is an Institutional Review Board approved retrospective cohort study looking at patients who were admitted to NYU Winthrop University Hospital and received at least one dose of antibiotics considered high risk of inducing CDI. Patients were grouped according to concurrent probiotic use and the association between probiotic use and incident CDI was examined.  A model for incident CDI adjusting for number of concurrent antibiotics, patient age, proton pump inhibitors, histamine receptor antagonists, presence of colitis, and chemotherapy was also estimated.  Microbiology reports were analyzed for up to 12 weeks post initial administration of antibiotics to determine if patient acquired CDI. If no CDI occurred during the admission or post discharge, data was censored at 12 weeks.

    Results: Of 2,208 patients, 1,502 (68%) were included in the interim analysis. 96 out of 1,502 patients (6.39%) had CDI within 12 weeks of antibiotics initiation. 135 (9%) were on probiotics during antibiotic use and 1,367 (91%) were not. Of those taking probiotics, 11.1% had an incident of CDI and of those not taking probiotics, 5.9% had an incident of CDI with a relative risk of 1.88 (1.11, 3.16) and a p-value = 0.02. After adjustment, although a positive association between probiotics and CDI was still observed, it was not statistically significant (p=0.24)

    Conclusion: Based on the interim analysis probiotics were associated with a higher risk of CDI in univariate analysis, however, when adjusted for several confounding factors this association, while still positive, was no longer statistically significant. Further data collection is ongoing to corroborate these results.

    Temima Saltzman, PharmD1, Sharon Blum, PharmD1, Burke A. Cunha, MD, FIDSA, FSHEA2, Melissa Fazzari, PhD3 and Shirley Chung, PharmD candidate4, (1)Pharmacy, NYU Winthrop Hospital, Mineola, NY, (2)NYU Winthrop Hospital, State University of New York School of Medicine at Stony Brook, Mineola, NY, (3)NYU Winthrop Hospital, Mineola, NY, (4)St. John's University College of Pharmacy, Flushing, NY


    T. Saltzman, None

    S. Blum, None

    B. A. Cunha, None

    M. Fazzari, None

    S. Chung, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.